The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer

International Journal of Oncology

Volumn 43, Issue 5, 2013, Pages 1627-1635

  Zhang, Chang Hua ^a,b,d   Awasthi, Niranjan ^a,b   Schwarz, Margaret A ^c   Schwarz, Roderich E ^a,b,e  

^a Division of Surgical Oncology   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^e INDIANA UNIVERSITY   (United States)

Author keywords

BEZ235; Chemotherapy; Gastric cancer; Nab paclitaxel; PI3K mTOR

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; ALBUMIN; CASPASE 3; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PACLITAXEL; PADELIPORFIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; S6 KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; ENZYME PHOSPHORYLATION; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; HUMAN CELL; IC 50; IMMUNOBLOTTING; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; SURVIVAL TIME; TUMOR XENOGRAFT;

ALBUMINS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FEMALE; HUMANS; IMIDAZOLES; MICE; MICE, INBRED NOD; MICE, SCID; NANOPARTICLES; PACLITAXEL; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; QUINOLINES; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84885064422     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2099     Document Type: Article

References (44)

1. Oh SC: Update of adjuvant chemotherapy for resected gastric cancer. J Gastric Cancer 12: 3-6, 2012.
2. Schwarz RE and Smith DD: Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. Ann Surg Oncol 14: 317-328, 2007.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
4. Pyrhonen S, Kuitunen T, Nyandoto P and Kouri M: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71: 587-591, 1995.
5. Matsubara J, Shimada Y, Kato K, et al: Phase II study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel as first-line therapy for advanced gastric cancer. Oncology 81: 291-297, 2011.
6. Boku N, Yamamoto S, Fukuda H, et al: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10: 1063-1069, 2009.
7. Ohtsu A, Shah MA, Van Cutsem E, et al: Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29: 3968-3976, 2011.
8. Okada K, Fujiwara Y, Takahashi T, et al: Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer. Ann Surg Oncol 20: 1035-1043, 2013.
9. Elsadek B and Kratz F: Impact of albumin on drug delivery - new applications on the horizon. J Control Release 157: 4-28, 2012.
10. Gradishar WJ, Tjulandin S, Davidson N, et al: Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23: 7794-7803, 2005.
11. Gradishar WJ: Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 7: 1041-1053, 2006.
12. Coleman RL, Brady WE, McMeekin DS, et al: A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 122: 111-115, 2011.
13. Kottschade LA, Suman VJ, Amatruda T III, et al: A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group Study, N057E (1). Cancer 117: 1704-1710, 2011.
14. Socinski MA, Bondarenko I, Karaseva NA, et al: Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 30: 2055-2062, 2012.
15. Volk LD, Flister MJ, Chihade D, Desai N, Trieu V and Ran S: Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases. Neoplasia 13: 327-338, 2011.
16. Von Hoff DD, Ramanathan RK, Borad MJ, et al: Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 29: 4548-4554, 2011.
17. Zhang C, Awasthi N, Schwarz MA, Hinz S and Schwarz RE: Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer. PLoS One 8: e58037, 2013.
18. Awasthi N, Yen PL, Schwarz MA and Schwarz RE: The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer. J Cell Biochem 113: 784-791, 2012.
19. Byun DS, Cho K, Ryu BK, et al: Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma. Int J Cancer 104: 318-327, 2003.
20. Li VS, Wong CW, Chan TL, et al: Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer 5: 29, 2005.
21. Smyth EC and Cunningham D: Targeted therapy for gastric cancer. Curr Treat Options Oncol 13: 377-389, 2012.
22. Wong H and Yau T: Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine? Oncologist 17: 346-358, 2012.
23. Serra V, Markman B, Scaltriti M, et al: NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68: 8022-8030, 2008.
24. Maira SM, Stauffer F, Brueggen J, et al: Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7: 1851-1863, 2008.
25. Jegg AM, Ward TM, Iorns E, et al: PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells. Breast Cancer Res Treat 136: 683-692, 2012.
26. Fuereder T, Wanek T, Pflegerl P, et al: Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake. Clin Cancer Res 17: 5322-5332, 2011.
27. Quintas-Cardama A and Verstovsek S: Molecular pathways: Jak/STAT pathway: mutations, inhibitors and resistance. Clin Cancer Res 19: 1933-1940, 2013.
28. Van de Bor V, Zimniak G, Cerezo D, Schaub S and Noselli S: Asymmetric localisation of cytokine mRNA is essential for JAK/STAT activation during cell invasiveness. Development 138: 1383-1393, 2011.
29. Xu R, Nakano K, Iwasaki H, et al: Dual blockade of phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways overcomes paclitaxel-resistance in colorectal cancer. Cancer Lett 306: 151-160, 2011.
30. Kim SH, Juhnn YS and Song YS: Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells. Ann NY Acad Sci 1095: 82-89, 2007.
31. Sun H, Yu T and Li J: Co-administration of perifosine with paclitaxel synergistically induces apoptosis in ovarian cancer cells: more than just AKT inhibition. Cancer Lett 310: 118-128, 2011.
32. Hou H, Zhang Y, Huang Y, et al: Inhibitors of phosphatidylinositol 3'-kinases promote mitotic cell death in HeLa cells. PLoS One 7: e35665, 2012.
33. Awasthi N, Schwarz MA, Verma V, Cappiello C and Schwarz RE: Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling. Lab Invest 89: 38-46, 2009.
34. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
35. Awasthi N, Zhang C, Ruan W, Schwarz MA and Schwarz RE: BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer. Mol Cancer Ther 11: 2644-2653, 2012.
36. Zhang C, Awasthi N, Schwarz MA and Schwarz RE: Establishing a peritoneal dissemination xenograft mouse model for survival outcome assessment of experimental gastric cancer. J Surg Res 182: 227-234, 2013.
37. Zhang CH, Zhan WH, He YL, Chen CQ, Huang MJ and Cai SR: Spleen preservation in radical surgery for gastric cardia cancer. Ann Surg Oncol 14: 1312-1319, 2007.
38. Xu J, Zhang C, He Y, et al: Lymphatic endothelial cell-secreted CXCL1 stimulates lymphangiogenesis and metastasis of gastric cancer. Int J Cancer 130: 787-797, 2012.
39. Schwarz RE and Zagala-Nevarez K: Recurrence patterns after radical gastrectomy for gastric cancer: prognostic factors and implications for postoperative adjuvant therapy. Ann Surg Oncol 9: 394-400, 2002.
40. Hofheinz RD, Wenz F, Lukan N, et al: Oxaliplatin and capecitabine-based chemoradiotherapy for gastric cancer - an extended phase I MARGIT and AIO trial. Int J Radiat Oncol Biol Phys 73: 142-147, 2009.
41. Kobunai T, Watanabe T and Fukusato T: Antitumour activity of S-1 in combination with cetuximab on human gastric cancer cell lines in vivo. Anticancer Res 31: 3691-3696, 2011.
42. Mueller A, Bachmann E, Linnig M, et al: Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines. Cancer Chemother Pharmacol 69: 1601-1615, 2012.
43. Janku F, Tsimberidou AM, Garrido-Laguna I, et al: PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 10: 558-565, 2011.
44. Brito DA and Rieder CL: Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Curr Biol 16: 1194-1200, 2006.